Hansoh Pharma Raises HK$3.92 Billion via Share Placement; Viking Therapeutics' Stock Plunges 42.12% Following Disappointing Phase 2 Data for Oral GLP-1/GIP Agonist VK2735
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
LEPU BIOPHARMA
Innovative Oncology Treatment Product Developer
Amino Observation - Original Production by the Innovative Drug Team
Author |
Pharmaceutical companies accelerate financing.
On August 20, Hansoh Pharma announced that it would place 108 million shares at a price of HKD 36.30 per share, raising HKD 3.92 billion.
Weight-loss drugs have overly high expectations, making them prone to setbacks.
On August 19, Viking Therapeutics announced the latest Phase II clinical data for its oral GLP-1/GIP dual agonist VK2735 for weight loss. In terms of safety, the discontinuation rate ranged between 20-38%, with common side effects being gastrointestinal-related, occurring at a significantly higher rate than the safety data from Phase I clinical trials. Following this news, Viking Therapeutics' stock price plummeted by 42.12%.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) XtalPi collaborates with Dong-A to develop new drugs in immune and inflammation fields
On August 20, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with Dong-A ST, a leading pharmaceutical company in South Korea. Both parties will leverage XtalPi’s AI + robotics R&D platform and combine their respective strengths to jointly develop innovative therapies for immune and inflammatory diseases.
/ 02 /
Capital Information
1) Hansoh Pharma Raises HKD 3.92 Billion through Share Placement
On August 20, Hansoh Pharma announced the placement of 108 million shares at HKD 36.30 per share, raising HKD 3.92 billion.
2) LEPU BIOPHARMA Profits 29.3 Million Yuan
On August 20, LEPU BIOPHARMA released its half-year report for 2025. During the reporting period, the company's revenue reached 465 million yuan, approximately 3.5 times that of the same period in 2024; net profit was 29.3 million yuan, turning a loss into a profit.
/ 03 /
Pharmaceutical News
1) Savolitinib/Osimertinib Combination Therapy SANOVO China Phase III Study Completes Enrollment
On August 20, HUTCHMED announced that the combination therapy of Orpathys® (savolitinib) and Tagrisso® (osimertinib) for the first-line treatment of certain non-small cell lung cancer patients with epidermal growth factor receptor ("EGFR") mutations and MET overexpression in the SANOVO Phase III study in China has completed patient enrollment. The last patient in the study was enrolled on August 18, 2025.
2) Novartis' New Drug for IgA Nephropathy, Atrasentan, Approved for Marketing
On August 20, Novartis announced that Atrasentan (brand name Nourida) had been approved by the National Medical Products Administration for reducing proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of rapid disease progression.
/ 04 /
Overseas Pharma News
1) Viking's stock price plummeted by 42.12%
On August 19, Viking Therapeutics announced the latest Phase II clinical data for its oral GLP-1/GIP dual-target agonist VK2735 for weight loss. In terms of safety, the discontinuation rate ranged between 20-38%, with common side effects being gastrointestinal-related, occurring at a significantly higher rate than the safety data from Phase I clinical trials. Following this news, Viking Therapeutics' stock price plummeted by 42.12%.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
